SCHEMBL1099119

SCHEMBL1099119

CCS(=O)(=O)N(Cc1ccc(F)c(F)c1)c1sc2ccccc2c1C(C)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 6/20 0.43
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
BMP1 P13497 2/20 0.35
RIPK1 Q13546 1/20 0.34
HTT P42858 2/20 0.33
MAPT P10636 3/20 0.33
S1PR3 Q99500 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
GRM2 Q14416 3/20 0.32
LMNA P02545 2/20 0.32
MEN1 O00255 1/20 0.32
MAPK1 P28482 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GLA P06280 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1099037 0.91 TRPM8 (0.43) TRPM8PTGS1PTGS2BMP1HTT
SCHEMBL10299814 0.89 TRPM8 (0.56) TRPM8
SCHEMBL10299811 0.89 TRPM8 (0.56) TRPM8
SCHEMBL1099840 0.89 TRPM8 (0.56) TRPM8
SCHEMBL10299819 0.89 TRPM8 (0.56) TRPM8
SCHEMBL1099436 0.89 TRPM8 (0.40) TRPM8MAPTLMNASMN1; SMN2
SCHEMBL1099398 0.88 TRPM8 (0.54) TRPM8BMP1LMNAMEN1KMT2A
SCHEMBL1099154 0.85 TRPM8 (0.36) TRPM8GRM2ALOX15TSHR
SCHEMBL1107220 0.84 TRPM8 (0.45) TRPM8PTGS1PTGS2BMP1RIPK1
SCHEMBL1099986 0.84 TRPM8 (0.55) TRPM8PTGS1PTGS2RIPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885PTGS1 308/4885PTGS2 382/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885PTGS1 308/4885PTGS2 382/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885PTGS1 308/4885PTGS2 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.